News Headlines
-
ANGLE Plc Announces New Commercial Agreement With AstraZeneca
4/24/2024
ANGLE plc a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR.
-
Kühne Holding Acquires Pharma Contract Manufacturer Aenova From BC Partners
4/24/2024
Kühne Holding AG has entered into a definitive agreement to acquire pharma contract development and manufacturing organization Aenova Group from leading international investment firm BC Partners. As part of the transaction, BC Partners’ advised funds will reinvest alongside Kühne Holding AG and continue to support Aenova as a minority shareholder.
-
Multiply Labs And GenScript Biotech Corporation Collaborate To Automate The Cell Isolation And Enrichment Phase Of Cell Therapy Manufacturing
4/23/2024
GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, and Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
-
Evotec SE Appoints Dr Christian Wojczewski As Chief Executive Officer
4/23/2024
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.
-
Vertex And TreeFrog Therapeutics Announce Licensing Agreement And Collaboration To Optimize Production Of Vertex’s Cell Therapies For Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex’s cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies.
-
Hanmi Enters Into Clinical Trial Collaboration And Supply Agreement With MSD To Evaluate BH3120 In Combination With KEYTRUDA® (pembrolizumab)
4/23/2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).
-
Bristol Myers Squibb And Cellares Announce A $380M Worldwide Capacity Reservation And Supply Agreement For The Manufacture Of CAR T Cell Therapies To Bring The Promise Of Cell Therapy To More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
PharmaLogic Announces Opening Of New State-Of-The-Art Radiopharmaceutical Production Facility In Cincinnati
4/22/2024
PharmaLogic Holdings Corp., ("PharmaLogic" or "the company"), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, announced the opening of its new radiopharmaceutical production and research facility in Cincinnati, Ohio.
-
Lilly Acquires New Injectable Medicine Manufacturing Facility From Nexus Pharmaceuticals
4/22/2024
Eli Lilly and Company and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.
-
Amicus Therapeutics Inc And Almac Pharma Services Mark 15-Year Strategic Partnership With Patient Advocacy Event
4/22/2024
Almac Pharma Services, a member of the privately owned Almac Group providing innovative pharmaceutical development, manufacture and commercial services to global pharmaceutical and biotech organisations, has celebrated a key milestone of its strategic partnership with global biotechnology company, Amicus Therapeutics Inc, by hosting a patient advocacy event for its employees.